Oncology News Central Peer-Spectives
oleh Oncololgy News Central
Episode terbaru
How Are Oncologists Managing Amivantamab Plus Lazertinib in EGFR…
How Are Oncologists Managing Amivantamab Plus Lazertinib in EGFR…
Tentang podcast ini
Peer-Spectives is a podcast series that is moderated by Robert Figlin, MD, and features various oncology thought-leaders covering the latest clinical developments in a wide range of tumor types.
Episode
20 episode terbaru dari 100
- How Are Oncologists Managing Amivantamab Plus Lazertinib in EGFR- Mutant NSCLC? · 15 mnt · Episode 36Recording live at the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea, Estelamari Rodriguez, MD, MPH, from the Sylvester Comprehensive Cancer Center at the…
- Who Still Needs Monotherapy in EGFR- Mutant NSCLC · 14 mnt · Episode 35Recording live at the 2026 World Conference on Lung Cancer in Seoul, South Korea, Estelamari Rodriguez, MD, MPH, from Sylvester Comprehensive Cancer Center, along with Misako…
- Is It Time for a New Type of Cancer Physician? · 16 mnt · Episode 32The dramatic increase in cancer survivorship is introducing questions about the ability of physicians to meet patient needs. “Maybe we need to have a survivor cancer patient see…
- What the “Tsunami” of Cancer Survivors Means for Oncologists · 13 mnt · Episode 33Advances in cancer treatments have led to a rising “tsunami” of survivors, which has introduced a new set of challenges for oncologists. Saro H. Armenian, DO, MPH, discusses what…
- “Sobering” Takeaway From ASCO 2026: Concerns About Clinical Trial Participation · 15 mnt · Episode 34Amid the exciting advances at ASCO 2026, there came a “sobering moment” regarding the U.S.’s role as a cancer clinical trial leader, says Robert A. Winn, MD. He discusses what…
- “A Lot More Asymptomatic Cancer Out There”: Major MCED Trial Hints at Complicated Future · 15 mnt · Episode 31The prospective randomized NHS-Galleri multicancer early detection trial didn’t meet its primary endpoint, but it did uncover a lot more early-stage cancers than predicted. Eric…
- “The Ever-Shifting and Chaotic” State of CLL Care: What New Data Mean for Practice · 14 mnt · Episode 30Data presented at the 2026 American Society of Clinical Oncology Annual Meeting add to the “ever-shifting and chaotic space” that is CLL care, says Matthew Lunning, DO. He…
- How “Drastically Better” Treatments for Some Colorectal Cancers Are Changing Care · 16 mnt · Episode 29New treatments for patients with microsatellite instability–high colorectal cancer are drastically changing outcomes. Nicholas James Hornstein, MD, PhD, discusses recent advances…
- “Not a Straightforward Decision”: What to Do While Waiting on a Practice Change in Breast Cancer Care · 11 mnt · Episode 28In the wake of recent key data about ESR1-mutated metastatic breast cancer, treatment decisions have become more complicated. “In current clinical practice, this is not a…
- New Targeted Therapies Make Breast Cancer Treatment Decisions “a Bit of a Moving Target” · 9 mnt · Episode 27“In breast cancer now, all of our treatment for hormone receptor–positive metastaticdisease is a bit of a moving target because of new therapies that are available,”explains Hope…
- Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic · 12 mnt · Episode 26As the management of patients with ESR1-mutated metastatic breast cancer evolves,various questions have emerged in clinical practice. “It's a complex situation,” explainsHope S…
- Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care · 14 mnt · Episode 25How are oncologists currently approaching the care of patients with ESR1-mutated advanced breast cancer in practice? Erin Frances Cobain, MD, associate professor at the…
- Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC · 12 mnt · Episode 24Combination regimens improve survival in advanced EGFR-mutated NSCLC, but they also increase toxicity. Jorge Nieva, MD, shares how he talks with patients about potential adverse…
- “Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions · 15 mnt · Episode 21Tackling central nervous system (CNS) disease in EGFR-mutated non-small cell lung cancer “is a huge problem, both from a quality-of-life perspective for patients and also from a…
- Second-Line Options in EGFR-Mutated NSCLC: What’s the Right Sequence? · 13 mnt · Episode 22
- “Is the Juice Worth the Squeeze?”: Treatment Intensification for Advanced EGFRm NSCLC · 13 mnt · Episode 23With multiple regimens available for advanced EGFRm NSCLC, selecting the best regimen for an individual patient is key. Jorge Nieva, MD, tells host Aakash Desai, MD, MPH, that…
- As Terminal Patients Live Longer, How Can Oncologists Help Them Cope With Uncertainty? · 16 mnt · Episode 20Progress in cancer care means that millions of patients are living longer lives, albeit without hope of a cure. What role can oncologists and other physicians play in helping to…
- Should Patients With Cancer Receive mRNA Vaccines Alongside Immunotherapy? · 13 mnt · Episode 19A recent study found a link between mRNA vaccination and improved cancer immunotherapy response. The preclinical data demonstrated impressive results, leading to big questions…
- Big News From ESMO 2025 Changes Practice in Bladder Cancer · 12 mnt · Episode 18Survival data from the KEYNOTE-905 trial and insights into the use of circulating tumor DNA to guide treatment decisions from IMvigor011 made big waves in bladder cancer care at…
- Big Changes in AML Care as Targeted Therapy Options Expand · 11 mnt · Episode 17Options for the treatment of acute myeloid leukemia (AML) are rapidly expanding, says Amir Fathi, MD, associate professor of medicine at Harvard Medical School in Boston and…








